Delisting risk
Evogene
AI-guided small-molecule discovery for medicines and crop protection.
$0.5490
After-hours close+0.01 (+1.48%)
At close$0.5410(+0.56%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions —Insiders 15.61%
Shares outstanding 8.62M · Float —
Institutions13F
No 13F holders on record.
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| L.I.A. Pure Capital Ltd.incl. Ron Yair Peled, Kfir Silberman +1 more | 19.35% | 3.06M | 13D | Aug 28, 2026 ↗ |
| Armistice Capital, LLC | 9.99% | 1.10M | 13G | May 15, 2026 ↗ |
| Recanati Leon | 8.60% | 1.35M | 13D | Aug 13, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Leon Recanati | director | 1.34M | 15.60% | Aug 13, 2026 |
| Gabi Tarcic | officer: Chief Development Officer | 1.1K | 0.01% | Aug 26, 2026 |
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 4, 2026 | Gabi Tarcicofficer: Chief Development Officer | Purchase | 1,129 | $0.6000 | 1,129 |
| Aug 11, 2026 | Leon Recanatidirector | Purchase | 460,000 | $0.6350 | 1,343,886 |
| Aug 4, 2026 | Leon Recanatidirector | Purchase | 800,000 | $0.5000 | 883,886 |
CongressHouse and Senate disclosures
Not reported.